PFEPfizerRunning, no new patients
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Breast Cancer · Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 74 (final count)
- Started
- Jun 30, 2025
- Main results expected
- Oct 25, 2027
- Fully finished
- Jan 27, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response (OR) by investigator assessment
Measured over: From Cycle 1 Day 1 until disease progression by investigator assessment per RECIST version 1.1, or death due to any cause, whichever is earlier; up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06966453 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC